5 ml of the syrup contains 1.25 mg of triprolidine hydrochloride (Triprolidini hydrochloridum), 30 mg of pseudoephedrine hydrochloride (Pseudoephedrini hydrochloridum) and 10 mg of dextromethorphan hydrobromide (Dextromethorphani hydrobromidum).
Symptomatic treatment in inflammation of the upper respiratory tract (flu, cold and other infections of the upper airways) with cough, swelling of the nasal mucosa and nasal watery mucus discharge.
Hypersensitivity to any of the active substances or excipients. Concomitant administration of monoamine oxidase inhibitors (MAOIs) and for two weeks following discontinuation of MAO therapy. Bronchial asthma. Acute liver or kidney failure. Existing or risk of respiratory failure. Coughing with a lot of discharge and associated with bronchial asthma. Severe hypertension. Severe ischemic heart disease. Mucoviscidosis. The medicinal product should not be used during pregnancy and lactation and in children under 7 years of age.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl
5 ml of the syrup contains 1.25 mg of triprolidine hydrochloride (Triprolidini hydrochloridum), 30 mg of pseudoephedrine hydrochloride (Pseudoephedrini hydrochloridum) and 10 mg of dextromethorphan hydrobromide (Dextromethorphani hydrobromidum).
Symptomatic treatment in inflammation of the upper respiratory tract (flu, cold and other infections of the upper airways) with cough, swelling of the nasal mucosa and nasal watery mucus discharge.
Hypersensitivity to any of the active substances or excipients. Concomitant administration of monoamine oxidase inhibitors (MAOIs) and for two weeks following discontinuation of MAO therapy. Bronchial asthma. Acute liver or kidney failure. Existing or risk of respiratory failure. Coughing with a lot of discharge and associated with bronchial asthma. Severe hypertension. Severe ischemic heart disease. Mucoviscidosis. The medicinal product should not be used during pregnancy and lactation and in children under 7 years of age.
Przedsiębiorstwo Produkcji
Farmaceutycznej
Hasco-Lek S.A.
st. Żmigrodzka 242e
51-131 Wroclaw
phone: (+48) 71 352 95 22
fax: (+48) 71 352 76 36
hasco@hasco-lek.pl
